Cantor Fitzgerald lowered the firm’s price target on Legend Biotech (LEGN) to $74 from $75 and keeps an Overweight rating on the shares. Despite heightened discussion around competition at ASH, Legend Biotech’s management highlighted Carvykti’s differentiation through long-term data, a broad label, and demonstrated survival benefit, the analyst tells investors in a research note. Management also emphasized the company’s ability to scale production to meet rising real-time demand in the multiple myeloma market.
Claim 50% Off TipRanks Premium and Invest with Confidence
- Unlock hedge-fund level data and powerful investing tools designed to help you make smarter, sharper decisions
- Stay ahead of the market with the latest news and analysis so your portfolio is always positioned for maximum potential
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
Read More on LEGN:
- Legend Biotech management to meet with Cantor Fitzgerald
- Legend Biotech price target lowered to $50 from $83 at Morgan Stanley
- Carvykti strength holds, Legend Biotech weakness overdone, says RBC Capital
- Midday Fly By: IBM to buy Confluent, Paramount goes hostile for Warner Bros.
- Legend Biotech falls -13.4%